DPYD
Testing: Time to Put Patient Safety First
J Clin Oncol
.
2023 May 20;41(15):2701-2705.
doi: 10.1200/JCO.22.02364.
Epub 2023 Feb 23.
Authors
Sharyn D Baker
1
,
Susan E Bates
2
,
Gabriel A Brooks
3
,
William L Dahut
4
,
Robert B Diasio
5
,
Wafik S El-Deiry
6
,
William E Evans
7
,
William D Figg
8
,
Dan L Hertz
9
,
J Kevin Hicks
10
,
Suneel Kamath
11
,
Pashtoon Murtaza Kasi
12
,
Todd C Knepper
10
,
Howard L McLeod
13
,
Peter H O'Donnell
14
,
Mary V Relling
7
,
Michelle A Rudek
15
,
Tristan M Sissung
8
,
D Max Smith
16
,
Alex Sparreboom
1
,
Sandra M Swain
16
,
Christine M Walko
10
Affiliations
1
College of Pharmacy, The Ohio State University, Columbus, OH.
2
Herbert Irving Comprehensive Cancer Center, Columbia University, Irving Medical Center, New York, NY.
3
Dartmouth Cancer Center, Geisel School of Medicine, Lebanon, NH.
4
American Cancer Society, Atlanta, GA.
5
College of Medicine and Science, Mayo Clinic, Rochester, MN.
6
Legorreta Cancer Center, Brown University, Providence, RI.
7
St. Jude Children's Research Hospital, Memphis, TN.
8
Clinical Pharmacology Program, National Cancer Institute, Bethesda, MD.
9
College of Pharmacy, University of Michigan, Ann Arbor, MI.
10
Department of Individualized Cancer Management, Moffitt Cancer Center, Tampa, FL.
11
Cleveland Clinic, Lerner College of Medicine, Cleveland, OH.
12
Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY.
13
Intermoutain Healthcare, St George, UT.
14
The University of Chicago, Chicago, IL.
15
School of Medicine, Johns Hopkins University, Baltimore, MD.
16
Georgetown Lombardi Comprehensive Cancer Center and MedStar Health, Georgetown University, Washington, DC.
PMID:
36821823
PMCID:
PMC10414691
DOI:
10.1200/JCO.22.02364
No abstract available
MeSH terms
Capecitabine
Dihydrouracil Dehydrogenase (NADP) / genetics
Fluorouracil*
Genotype
Humans
Patient Safety*
Substances
Fluorouracil
Capecitabine
Dihydrouracil Dehydrogenase (NADP)